Synmosa Biopharma Corporation (TPEX:4114)

Market Cap	18.10B
Revenue (ttm)	6.00B
Net Income (ttm)	725.80M
Shares Out	500.70M
EPS (ttm)	1.52
PE Ratio	23.80
Forward PE	n/a
Dividend	0.55 (1.48%)
Ex-Dividend Date	Jul 11, 2025

Volume	3,107,208
Average Volume	2,363,819
Open	36.90
Previous Close	36.90
Day's Range	36.00 - 36.90
52-Week Range	24.33 - 39.80
Beta	0.01
RSI	50.53
Earnings Date	Aug 11, 2025

About Synmosa Biopharma

Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, such as effervescent tablets, granules, nasal sprays, metered dosed inhalers, sex hormones, and other forms. In addition, it offers contract manufacturing...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4114

Financial Performance

In 2024, Synmosa Biopharma's revenue was 5.55 billion, an increase of 7.96% compared to the previous year's 5.14 billion. Earnings were 684.68 million, an increase of 15.11%.